At Siolta Therapeutics, we are leveraging our knowledge of the infant gut microbiome to develop live biotherapeutic products for the prevention and treatment of inflammatory diseases. Our team has developed a three phase approach for microbiome-based live biotherapeutic drug development.
First, we collect and analyze longitudinal microbiome data from infants to identify the communities of microbes, and specific bacterial strains, that promote health during early infant development. In our second phase, we validate the beneficial immunomodulatory capacity of the protective microbial communities identified in phase 1. Once validated, we isolate and characterize the keystone species within these protective microbial communities. We build a portfolio of data on these strains, including what they like to eat, what they produce, who their microbial friends are, and how they interact with the human immune system. We perform this characterization to aid our scientists in phase three of our development pipeline, the rational design of mixed-species live bacterial therapeutics. In phase three, we develop live mixed-species microbial therapeutics that are administered in clinical trials aimed to evaluate their safety and efficacy in human as novel treatments for disease.
Biotherapeutic products for the prevention and treatment of inflammatory diseases